Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial

PURPOSE: Alisertib is an oral Aurora A kinase inhibitor with preclinical activity in neuroblastoma. Irinotecan and temozolomide have activity in patients with advanced neuroblastoma. The goal of this phase I study was to determine the maximum tolerated dose (MTD) of alisertib with irinotecan and tem...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Oncol
Main Authors: DuBois, Steven G., Marachelian, Araz, Fox, Elizabeth, Kudgus, Rachel A., Reid, Joel M., Groshen, Susan, Malvar, Jemily, Bagatell, Rochelle, Wagner, Lars, Maris, John M., Hawkins, Randall, Courtier, Jesse, Lai, Hollie, Goodarzian, Fariba, Shimada, Hiroyuki, Czarnecki, Scarlett, Tsao-Wei, Denice, Matthay, Katherine K., Mosse, Yael P.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2016
Fag:
ORIGINAL REPORTS
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872349/
https://ncbi.nlm.nih.gov/pubmed/26884555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.65.4889
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker